DeuteRx is focused on 'deuterium-enabled chiral switching' (DECS), an approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therape...Show all
Company (Alive / Active)
Phone: 978-662-5287
300 Brickstone Square
Suite 201
Andover, 01810
Massachusetts, United States
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Investor | Investor Type | Location | Participating Rounds |
---|
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Deuterium-enriched pioglitazone | Mar 12, 2018 | Mar 03, 2020 | Patent |
3-(substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | Nov 10, 2017 | Feb 11, 2020 | Patent |
5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | Nov 07, 2017 | Apr 23, 2019 | Patent |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | Dec 15, 2016 | Feb 12, 2019 | Patent |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4h)-yl-piperidinonyl conjugates and methods of treating medical disorders using same | Oct 13, 2017 | Jan 29, 2019 | Patent |